IRD Projected Dividend Yield

Opus Genetics Inc ( NASDAQ : IRD )

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Co.'s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1? and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR.

21 YEAR PERFORMANCE RESULTS